Epitope mapping – Instrumental in therapeutic antibody development
Recently, we launched a worldwide campaign to stress the importance of epitope mapping in therapeutic antibody development. Part of this campaign is a movie featuring Dr. Dennis Flierman (Director Epitope Mapping) and Dr. Marty Wulferink (European and Dutch patent attorney).
Epitope mapping not only plays a key role in functional understanding and selection of antibodies, but also in IP protection and FDA/EMA approval. Recent patent disputes have illustrated the necessity of epitope mapping in protecting a company’s interests. It is therefore surprising that only 10% of the antibody filings mentions epitope mapping.
In 2019, Pepscan was the epitope mapping company of choice, based on filings that mentioned epitope mapping. As one of the market leaders, we therefore feel the responsibility to increase awareness about the instrumental role of epitope mapping in communities of scientists, businesses and regulatory communities within the biotech and pharmaceutical industry.
Pepscan invented peptide-based epitope mapping, and builds on 25 years in advanced and applied peptide chemistry. Combining our scientists’ experience and expertise with our in-house developed peptide arrays and proprietary CLIPS™ technology, we can define linear, conformational or discontinuous epitopes accurately and cost-effectively.